MoonLake Immunotherapeutics (MLTX) stock
MLTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$12.50−0.37 (-2.87%)
Close on Nov 13, 2026Market cap $1.06BP/E –Yield –
MoonLake Immunotherapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
MoonLake Immunotherapeutics's enterprise value was $396.97M on Nov 11, 2026, against $490.08M a year earlier. Over the last 5 years it ranged from $27.87M to $4.00B, with a median of $1.50B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $396.97M | -12.8% |
| 2025 | Dec 31, 2025 | $455.30M | -84.2% |
| 2024 | Dec 31, 2024 | $2.88B | +29.0% |
| 2023 | Dec 29, 2023 | $2.23B | +1041.8% |
| 2022 | Dec 30, 2022 | $195.27M | +599.3% |
| 2021 | Dec 31, 2021 | $27.93M | – |
See a number that looks wrong?